Literature DB >> 28552381

Influence of Maternal Body Mass Index and Macrophage Activation on Asthma Exacerbations in Pregnancy.

Vanessa E Murphy1, Megan E Jensen2, Heather Powell3, Peter G Gibson3.   

Abstract

BACKGROUND: Obesity is a risk factor for exacerbations of asthma, but the mechanisms of this effect in pregnancy are unknown.
OBJECTIVE: This study determined the influence of maternal body mass index, gestational weight gain, eosinophilic inflammation, and systemic macrophage activation on the risk of exacerbations during pregnancy.
METHODS: Women with asthma (n = 164) participated in the study. Body mass index recorded at baseline (17 weeks gestation) was categorized as healthy weight (18.5-24.9 kg/m2), overweight (25-29.9 kg/m2), or obese (>30 kg/m2). Exacerbations requiring medical intervention were recorded prospectively. Asthma control, medication use, and fractional exhaled nitric oxide were assessed monthly; additional visits occurred during exacerbations. Peripheral blood was collected at baseline for the measurement of eosinophils, soluble CD-163, C-reactive protein, and IL-6.
RESULTS: Exacerbations occurred in a higher proportion of overweight (51.1%) and obese (48.4%) women compared with healthy weight women (25%; P = .026). Excess weight gain during pregnancy was not associated with exacerbation risk. Macrophage activation (elevated serum soluble CD-163) was associated with exacerbations requiring oral corticosteroids (P = .043), whereas high peripheral blood eosinophils or fractional exhaled nitric oxide were not associated with exacerbation or oral corticosteroid use.
CONCLUSIONS: Being overweight or obese confers a greater risk of asthma exacerbation during pregnancy, and may be due to systemic macrophage activation.
Copyright © 2017 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Asthma; CD163; Eosinophil; Exacerbation; Exhaled nitric oxide; Inflammation; Macrophage; Pregnancy

Mesh:

Substances:

Year:  2017        PMID: 28552381     DOI: 10.1016/j.jaip.2017.03.040

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  7 in total

1.  Gestational and Postpartum Weight Trajectories Among Women With and Without Asthma.

Authors:  Danielle R Stevens; William Grobman; Rajesh Kumar; Leah M Lipsky; Stefanie N Hinkle; Zhen Chen; Andrew Williams; Matthew C H Rohn; Jenna Kanner; Seth Sherman; Pauline Mendola
Journal:  Am J Epidemiol       Date:  2021-05-04       Impact factor: 4.897

2.  Determining the Clinical Course of Asthma in Pregnancy.

Authors:  Danielle R Stevens; Neil Perkins; Zhen Chen; Rajesh Kumar; William Grobman; Akila Subramaniam; Joseph Biggio; Katherine L Grantz; Seth Sherman; Matthew Rohn; Pauline Mendola
Journal:  J Allergy Clin Immunol Pract       Date:  2021-10-14

3.  Risk factors for asthma exacerbation during pregnancy: protocol for a systematic review and meta-analysis.

Authors:  Marleen P Bokern; Annelies L Robijn; Megan E Jensen; Daniel Barker; Katherine J Baines; Vanessa E Murphy
Journal:  Syst Rev       Date:  2022-06-07

Review 4.  Maternal asthma and gestational diabetes mellitus: Exploration of potential associations.

Authors:  M E Jensen; H L Barrett; M J Peek; P G Gibson; V E Murphy
Journal:  Obstet Med       Date:  2020-06-18

Review 5.  Asthma in pregnancy: An update.

Authors:  Simon Couillard; Clare Connolly; Catherine Borg; Ian Pavord
Journal:  Obstet Med       Date:  2020-11-01

6.  Maternal body composition and gestational weight gain in relation to asthma control during pregnancy.

Authors:  Danielle R Stevens; Matthew C H Rohn; Stefanie N Hinkle; Andrew D Williams; Rajesh Kumar; Leah M Lipsky; William Grobman; Seth Sherman; Jenna Kanner; Zhen Chen; Pauline Mendola
Journal:  PLoS One       Date:  2022-04-20       Impact factor: 3.240

7.  Systemic corticosteroid therapy augments ex vivo release of sCD163 by peripheral blood monocytes of asthmatic patients.

Authors:  Paweł L Bernatowicz; Paweł Golec; Paweł Bielecki; Krzysztof Kowal
Journal:  Postepy Dermatol Alergol       Date:  2020-03-09       Impact factor: 1.837

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.